Christopher Shen

• Aleutian Therapeutics

Sources: reporter.nih.gov

• National Institute of Diabetes and Digestive and Kidney Diseases

  R41, Development of an immune evasive stem cell line for Type 1 diabetes regenerative therapy, R41DK142395, 2025–2027, 6 Sept 2025

• National Institute of Allergy and Infectious Diseases

  R41, Development of a gene edited platform to enable human allogeneic cell replacement therapy, R41AI192172, 2025–2026, 18 Aug 2025

• National Institute of Allergy and Infectious Diseases

  R41, Development of immune evasive strategies for allogeneic cell replacement therapies, R41AI191979, 2025–2026, 21 May 2025

Sources: reporter.nih.gov